Pharmacogenomics Journal

Papers
(The TQCC of Pharmacogenomics Journal is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
CYP3A5 and POR gene polymorphisms as predictors of infection and graft rejection in post-liver transplant patients treated with tacrolimus - a cohort study52
Drug genetic associations with COVID-19 manifestations: a data mining and network biology approach40
Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study24
Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests22
Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial21
Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis21
Genetic factors contributing to late adverse musculoskeletal effects in childhood acute lymphoblastic leukemia survivors19
Development of an extensive workflow for comprehensive clinical pharmacogenomic profiling: lessons from a pilot study on 100 whole exome sequencing data19
Genetic variants associated with cardiometabolic abnormalities during treatment with selective serotonin reuptake inhibitors: a genome-wide association study18
The expression level of Neuronal Calcium Sensor 1 can predict the prognosis of cytogenetically normal AML15
Correction to: One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective study15
Clinical utility of pharmacogenetics in a psychiatric and primary care population15
Knowledge and attitudes of medical and pharmacy students about pharmacogenomics: a systematic review and meta-analysis14
Inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T>C (rs11706052) and 12-month evolution of the graft function in renal transplant recipients on mycophenolate-based immunosuppress13
Clinical and economic outcomes of a pharmacogenomics-enriched comprehensive medication management program in a self-insured employee population12
Real-world economic evaluation of prospective rapid whole-genome sequencing compared to a matched retrospective cohort of critically ill pediatric patients in the United States12
Genetic association analysis and frequency of NUDT15*3 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease in a large Dutch cohort11
Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application11
AHR-dependent genes and response to MTX therapy in rheumatoid arthritis patients11
Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment of Slovenian patients undergoing kidney transplantation in the U-PGx PREPARE study10
HLA-DQA1*05 and upstream variants of PPARGC1B are associated with infliximab persistence in Japanese Crohn’s disease patients10
Correction to: A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM Plus platform10
Network pharmacology prediction, molecular docking and in vitro experiment explored the potential mechanism of Gaoyuan’an capsule in improving hypoxia tolerance10
Association between functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases: a meta-analysis10
Opioid use disorder risk alleles in self-reported assigned African American/Afro-Caribbean and European biogeographical genetic ancestry groups and in males and females9
Unveiling the association between HMG-CoA reductase inhibitors and bladder cancer: a comprehensive analysis using Mendelian randomization, animal models, and transcriptomics8
Evaluation of the EMPAR study population on the basis of metabolic phenotypes of selected pharmacogenes7
Targeted next-generation sequencing of genes involved in Warfarin Pharmacodynamics and pharmacokinetics pathways using the Saudi Warfarin Pharmacogenetic study (SWAP)7
Correction to: PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors7
Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension7
STRIPE partners in precision medicine series: pharmacist perspective7
Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment in Austrian kidney transplant recipients participating in the U-PGx PREPARE study6
Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study6
Correction to: Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review6
Pharmacogenomic study—A pilot study of the effect of pharmacogenomic phenotypes on the adequate dosing of verapamil for migraine prevention6
Genetic markers of early response to lurasidone in acute schizophrenia6
Cytochrome P450-2D6 activity in people with codeine use disorder6
Assessment of clinically actionable pharmacogenetic markers to stratify anti-seizure medications6
0.046011924743652